- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
Patent holdings for IPC class A61K 31/502
Total number of patents in this class: 1554
10-year publication summary
|
64
|
72
|
84
|
88
|
108
|
134
|
133
|
166
|
150
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| AstraZeneca AB | 2834 |
42 |
| MetrioPharm AG | 49 |
38 |
| Mirati Therapeutics, Inc. | 274 |
26 |
| F. Hoffmann-La Roche AG | 7895 |
21 |
| Amgen Inc. | 4278 |
20 |
| Novartis AG | 10511 |
15 |
| The Regents of the University of California | 20315 |
14 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
14 |
| Genentech, Inc. | 4011 |
13 |
| Daiichi Sankyo Company, Limited | 1876 |
13 |
| Rigel Pharmaceuticals, Inc. | 528 |
13 |
| The Johns Hopkins University | 5764 |
12 |
| KuDOS Pharmaceuticals Limited | 36 |
12 |
| Board of Regents, The University of Texas System | 5959 |
11 |
| Idience Co., Ltd. | 21 |
11 |
| Centre National de La Recherche Scientifique | 10726 |
10 |
| Takeda Pharmaceutical Company Limited | 2709 |
10 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 849 |
10 |
| Bergenbio ASA | 56 |
10 |
| Bristol-myers Squibb Company | 4793 |
9 |
| Other owners | 1230 |